Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced it ha
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase 3 IMforte trial Zepzelca and atezolizumab combination added to National Comprehensive Canc
US FDA approves Jazz Pharma's therapy for lung cancer
03:37pm, Thursday, 02'nd Oct 2025
The U.S. Food and Drug Administration on Thursday has expanded the approval for Jazz Pharmaceuticals' therapy as a maintenance treatment of adult patients with a type of lung cancer.
Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY Rating
10:45am, Wednesday, 24'th Sep 2025
Jazz Pharmaceuticals (JAZZ) receives a BUY rating, driven by strong DUET trial results for Xywav in narcolepsy and idiopathic hypersomnia. JAZZ's growth is anchored by Xywav and Epidiolex, both genera
Here's Why JAZZ Stock Is an Unconventional Cannabis Investment
09:45am, Wednesday, 24'th Sep 2025
Jazz Pharma is redefining cannabis investing with Epidiolex, a fast-growing FDA-approved epilepsy drug fueling its growth.
20 abstracts presented across World Sleep and Psych Congresses showcase Jazz's leadership in sleep medicine Novel results from the Phase 4 DUET trial underscore the significance of appropriate treatme
Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the United States For U.S. media and investors only DUBLIN , Sept. 9, 2025 /PRNewswire/
Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
01:21pm, Wednesday, 03'rd Sep 2025
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 9:30 AM EDT Company Participants Amal Melhem-Bertrandt Philip Johnson - Executive VP & CFO
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
04:15pm, Thursday, 21'st Aug 2025
DUBLIN , Aug. 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2025 Wells Fargo Healthcare Conference. Company management will
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
10:50am, Thursday, 21'st Aug 2025
Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
04:15pm, Wednesday, 20'th Aug 2025
DUBLIN , Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m.
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
07:30am, Wednesday, 20'th Aug 2025
Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales Jazz obtains exclusive worldwide rights to
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock
10:15am, Friday, 08'th Aug 2025
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an overall response rate in patien
US FDA approves Jazz Pharma's drug for rare brain tumor
03:00pm, Wednesday, 06'th Aug 2025
The U.S. Food and Drug Administration said on Wednesday that it has approved Jazz Pharmaceuticals' drug to treat diffuse midline glioma, a rare and aggressive tumor, in adults and children aged one ye
